FOR OVER A DECADE, YOU’VE RELIED
ON BRANDED AUBAGIO FOR YOUR RMS PATIENTS1
BRANDED AUBAGIO® (teriflunomide) IS SUPPORTED BY 18+ YEARS
OF COMBINED CLINICAL TRIAL AND REAL-WORLD EXPERIENCE1-4
*Patients either continued on their AUBAGIO dose, or those who received placebo were randomized to either AUBAGIO 14 mg or AUBAGIO 7 mg. In TOWER, all patients received AUBAGIO 14 mg, regardless of dose in the core trial.3,5,7,9
POOLED CORE SAFETY DATA
Serious adverse events occurred in 13%, 12%, and 12% of patients in the AUBAGIO 14 mg, AUBAGIO 7 mg, and placebo groups, respectively3
- Serious adverse events reported in AUBAGIO clinical trials included hepatotoxicity, infections, peripheral neuropathy, and blood pressure effects1
- Cases of bone marrow effects, hypersensitivity, skin reactions including a fatal case of toxic epidermal necrolysis, respiratory effects, drug-induced liver injury, and a fatal case of drug reaction with eosinophilia and systemic symptoms have been reported in patients taking AUBAGIO in the postmarketing setting1
- Medications like AUBAGIO may cause patients to be more susceptible to infections, including opportunistic infections1
- The most frequent adverse reactions (≥10% and ≥2% greater than placebo) with AUBAGIO 7 mg and 14 mg and placebo, respectively, were headache (18% and 16% vs 15%), ALT increased (13% and 15% vs 9%), diarrhea (13% and 14% vs 8%), alopecia (10% and 13% vs 5%), and nausea (8% and 11% vs 7%)1,3
- Overall discontinuation rates due to adverse events were 12.5% with AUBAGIO 14 mg, 11.2% with AUBAGIO 7 mg, and 7.5% with placebo, and treatment discontinuation rates due to common adverse events were ≤3.3% in the pooled clinical trials1,3
Four cardiovascular deaths, including 3 sudden deaths and 1 myocardial infarction in a patient with a history of hyperlipidemia and hypertension, were reported among approximately 2600 patients exposed to AUBAGIO in the premarketing database1
- A relationship between AUBAGIO and cardiovascular death has not been established
LONG-TERM SAFETY OVER 4 EXTENSION TRIALS
Phase II (~12 years of extension data): most common AEs were nasopharyngitis, hypoesthesia, fatigue, muscular weakness, and upper respiratory tract infection3
- Serious AEs: 48.1% of AUBAGIO 7 mg and 40.9% of AUBAGIO 14 mg patients3
TEMSO (~8 years of extension data): AEs occurred in ~93% of patients; overall discontinuation rates due to AEs were 12.6%3,5
- Serious AEs were 25% across treatment groups3,5
TOPIC (~5 years of extension data): AEs occurred in 79% of patients over the extension period7
- Overall, 13.5% of patients experienced serious AEs and 5.9% discontinued treatment because of AEs7
TOWER (~6 years of extension data): AEs occurred in ~79% of patients and overall discontinuation rates due to AEs were <8%9
- Serious AEs: <11% of patients across treatment groups9
- Most common AEs: nasopharyngitis (14%), headache (9%), diarrhea (9%), hair thinning (8%), and back pain (7%)9
THE AUBAGIO DATA WERE DEMONSTRATED ACROSS 4 CLINICAL TRIALS1
CORE + EXTENSION TRIAL DURATION: ~13 YEARS2,3
Data on 7 mg dose are not included in image above.
CORE + EXTENSION TRIAL DURATION: ~10.5 YEARS3,4
CORE + EXTENSION TRIAL DURATION: ~7 YEARS7
CORE + 6 YEARS EXTENSION TRIAL DURATION8
IS AN ORAL IMMUNOMODULATOR WITH ANTI-INFLAMMATORY PROPERTIES1
The immunomodulatory MOA of AUBAGIO is thought to inhibit proliferation of
autoreactive T and B cells1,10
PROPOSED AUBAGIO MECHANISM OF ACTION IN RMS1,10
- The exact mechanism by which AUBAGIO exerts its therapeutic effect in MS is not fully understood, but may involve a reduction in the number of activated T and B cells in the CNS1,10
- The salvage pathway is not affected by AUBAGIO; therefore, basic homeostatic cell functions of resting lymphocytes appear to be preserved10
AE=adverse event; ALT=alanine aminotransferase; CNS=central nervous system; DHODH=dihydroorotate dehydrogenase; MOA=mechanism of action.
AUBAGIO® (teriflunomide) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
IMPORTANT SAFETY INFORMATION
WARNING: HEPATOTOXICITY AND EMBRYOFETAL TOXICITY
- Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with AUBAGIO in the postmarketing setting. Concomitant use of AUBAGIO with other hepatotoxic drugs may increase the risk of severe liver injury.
- Obtain transaminase and bilirubin levels within 6 months before initiation of AUBAGIO therapy. Monitor ALT levels at least monthly for 6 months after starting AUBAGIO. If drug-induced liver injury is suspected, discontinue AUBAGIO and start an accelerated elimination procedure with cholestyramine or activated charcoal. AUBAGIO is contraindicated in patients with severe hepatic impairment. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking AUBAGIO.
- AUBAGIO is contraindicated for use in pregnant women and in women of reproductive potential who are not using effective contraception because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals at plasma teriflunomide exposure lower than that in humans. Exclude pregnancy before the start of treatment with AUBAGIO in females of reproductive potential. Advise females of reproductive potential to use effective contraception during AUBAGIO treatment and during an accelerated drug elimination procedure after AUBAGIO treatment. Stop AUBAGIO and use an accelerated drug elimination procedure if the patient becomes pregnant.
- Patients with severe hepatic impairment.
- Pregnant women and females of reproductive potential not using effective contraception.
- Patients with a history of hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in AUBAGIO.
- Co-administration with leflunomide.
WARNINGS AND PRECAUTIONS
- Hepatotoxicity: Clinically significant liver injury, which could be life-threatening, can occur at any time during treatment with AUBAGIO. Patients with pre-existing acute or chronic liver disease, or those with serum ALT >2 times the upper limit of normal (ULN) before initiating treatment, should not normally be treated with AUBAGIO. In clinical trials, if ALT elevation was >3 times the ULN on 2 consecutive tests, patients discontinued AUBAGIO and underwent accelerated elimination. Consider additional monitoring if co-administering AUBAGIO with other potentially hepatotoxic drugs; monitor patients who develop symptoms suggestive of hepatic dysfunction (eg, unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine).
- Embryofetal Toxicity: AUBAGIO may cause fetal harm when administered in pregnant women. Teratogenicity and embryofetal lethality occurred in animal reproduction studies in multiple animal species at plasma teriflunomide exposures similar to or lower than that in humans at the maximum human recommended dose of 14 mg/day. AUBAGIO is contraindicated for use in pregnant women and females of reproductive potential not using effective contraception. Exclude pregnancy before starting AUBAGIO in females of reproductive potential. Advise females of reproductive potential to use effective contraception during AUBAGIO treatment and during an accelerated drug elimination procedure (AEP) after AUBAGIO treatment. If a woman becomes pregnant while taking AUBAGIO, stop treatment, apprise patient of the potential risk to a fetus, and perform an AEP to achieve an AUBAGIO plasma concentration of <0.02 mg /L. Upon discontinuing AUBAGIO, it is recommended all females of reproductive potential undergo an AEP. Women receiving AUBAGIO who wish to become pregnant must discontinue AUBAGIO and undergo an AEP, until plasma concentrations of AUBAGIO are <0.02 mg /L. Men wishing to father a child should also stop AUBAGIO and either undergo an AEP or wait until plasma concentration of AUBAGIO is <0.02 mg/L. Women who become pregnant while taking AUBAGIO may enroll in the AUBAGIO pregnancy registry by calling 1‑800‑745‑4447, option 2.
- Procedure for Accelerated Elimination of Teriflunomide: Teriflunomide is eliminated slowly from the plasma—it takes an average of 8 months, or up to 2 years, to reach plasma concentrations <0.02 mcg /mL. Elimination may be accelerated by administration of cholestyramine or activated charcoal, but this may cause disease activity to return in patients who were responding to AUBAGIO.
- Bone Marrow Effects/Immunosuppression Potential/Infections: Decreases in white blood cell counts, mainly of neutrophils and lymphocytes, and platelets have been reported with AUBAGIO. Thrombocytopenia, including rare cases with platelet counts less than 50,000/mm3, has been reported in the postmarketing setting. Obtain a complete blood cell count within 6 months before starting treatment, with further monitoring based on signs and symptoms of bone marrow suppression. AUBAGIO is not recommended for patients with severe immunodeficiency, bone marrow disease, or severe uncontrolled infections. Tuberculosis (TB) has been observed in clinical studies of AUBAGIO. Before starting treatment, screen patients for latent TB infection with a tuberculin test. Treatment in patients with acute or chronic infections should not be started until the infection(s) is resolved. Administration of live vaccines is not recommended. The risk of malignancy, particularly lymphoproliferative disorders, or infection may be increased with the use of some medications with immunosuppressive potential, including teriflunomide.
- Hypersensitivity Reactions: AUBAGIO can cause anaphylaxis and severe allergic reactions. Signs and symptoms have included dyspnea, urticaria, and angioedema including lips, eyes, throat, and tongue. Inform patients of the signs and symptoms of anaphylaxis and angioedema.
- Serious Skin Reactions: Cases of serious skin reactions, sometimes fatal, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with AUBAGIO. Fatal outcomes were reported in one case of TEN and one case of DRESS. Inform patients of the signs and symptoms of a serious skin reaction and instruct them to discontinue AUBAGIO and seek immediate medical care. Unless the reaction is clearly not drug-related, discontinue AUBAGIO and begin accelerated elimination immediately. In such cases, patients should not be re-exposed to teriflunomide.
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): DRESS, also known as multiorgan hypersensitivity, has occurred with AUBAGIO. One fatal case of DRESS that occurred within 34 days of initiation of AUBAGIO treatment has been reported in the postmarketing setting. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity (eg, fever, lymphadenopathy) may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Discontinue AUBAGIO, unless an alternative etiology for the signs or symptoms is established, and begin an accelerated elimination procedure immediately. In such cases, patients should not be re-exposed to teriflunomide.
- Peripheral Neuropathy: Peripheral neuropathy, including polyneuropathy and mononeuropathy, has been reported with AUBAGIO. Age >60 years, concomitant neurotoxic medications, and diabetes may increase the risk. If peripheral neuropathy is suspected, consider discontinuing treatment and performing accelerated elimination.
- Increased Blood Pressure: Blood pressure increases and hypertension have occurred with AUBAGIO. Measure blood pressure at treatment initiation and manage any elevations during treatment.
- Respiratory Effects: Interstitial lung disease (ILD), including acute interstitial pneumonitis, has been reported with AUBAGIO. ILD may be fatal and may occur acutely at any time during therapy with a variable clinical presentation. If discontinuation of the drug is necessary, consider initiation of an accelerated elimination procedure.
- Pancreatitis in Pediatric Patients: AUBAGIO is not approved for use in pediatric patients. In a pediatric clinical trial, cases of pancreatitis were observed in patients receiving AUBAGIO. If pancreatitis is suspected, discontinue teriflunomide and start an accelerated elimination procedure.
Adverse Reactions: The most frequent adverse reactions (≥10% and ≥2% greater than placebo) with AUBAGIO 7 mg and 14 mg and placebo, respectively, were headache (18% and 16% vs 15%), ALT increased (13% and 15% vs 9%), diarrhea (13% and 14% vs 8%), alopecia (10% and 13% vs 5%), and nausea (8% and 11% vs 7%).
Drug Interactions: Monitor patients when teriflunomide is coadministered with warfarin, or with drugs metabolized by CYP1A2, CYP2C8, substrates of OAT3 transporters, substrates of BCRP, or OATP1B1/1B3 transporters.
Use in Specific Populations: Women should not breastfeed during treatment with AUBAGIO.
Please see Full Prescribing Information, including boxed WARNING.